Nuvectis Pharma, Inc. · NASDAQ:NVCT
Nuvectis Pharma — IPO Roadshow (November 2021)
24 slides from Nuvectis Pharma's IPO roadshow presentation, Nov 2, 2021
Slide 1: Innovative Precision Medicine for Serious Conditions of Unmet Medical Need in Oncology
1 SEPTEMBER 2021 Innovative Precision - Medicine for Serious Conditions Of Unmet Medical Need in Oncology NOVEMBER 2021 Innovative Precision Medicine for Serious Conditions Of Unmet Medical Need in Oncology
Slide 2: Forward-Looking Statements
Forward - Looking Statements Certain statements in this presentation constitute “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 , each as amended . Statements other than those of historical fact,
Slide 3: Free Writing Prospectus
Free Writing Prospectus This presentation highlights basic information about us and the proposed offering . Because it is a summary, it does not contain all of the information that you should consider before investing . The Company has filed with the U . S . Securities and Exchange Commission (the “
Slide 4: Offering Summary
4 Offering Summary Issuer Nuvectis Pharma Inc. Proposed Offering Common Stock Price Range $12.00 - $14.00 Proposed Symbol NVCT Shares Offered 2,300,000 Pre - IPO Common Shares Outstanding 9,517,794 Use of Proceeds • Fund Phase 1/2 development of NXP800 • Fund IND - enabling studies of NXP900 • Gener
Slide 5: Key Highlights
5 Innovative Precision Medicine for Serious Conditions of Unmet Medical Needs in Oncology Key Highlights • Management team with proven track record of clinical and regulatory success and significant shareholder value creation • Novel pipeline of precision targeted therapy drug candidates • NXP800: A
Slide 6: Nuvectis Pipeline
Nuvectis Pipeline 6 Unique precision - medicine drug candidates
Slide 7: Leadership Team
Leadership Team Track Record of Success Ron Bentsur CHAIRMAN AND CEO has over 20 years of senior leadership experience in the biopharmaceutical industry: CEO of UroGen Pharma, (NASDAQ : URGN), CEO of Keryx Biopharmaceuticals, (NASDAQ:KERX, acquired by Akebia Therapeutics). Mr. Bentsur served on the
Slide 8: Leadership Team (cont.)
Leadership Team (cont.) Track Record of Success 8 2 Breakthrough Therapy Designations in oncology. Multiple Orphan Drug Designation (US/EU) and Fast Track Designations (US) Team Achievements 4 FDA approvals 2 EU approvals 1 approval in Japan (via partner) Proven significant shareholder value creatio
Slide 9: NXP800 Key Highlights
NXP800 Key Highlights Discovered and optimized at the Institute of Cancer Research (ICR) in the UK. The ICR discovered Zytiga, a leading drug for metastatic prostate cancer. Unique, novel molecule targeting a well - characterized biologic pathway with established relevance in oncology: Heat Shock Fa
Slide 10: Targeting the HSF1 Pathway in Oncology
Targeting the HSF1 Pathway in Oncology HSF1 Activity Anti - apoptosis Mutation / Aneuploidy Proliferation & Signaling Oxidative & Hyptonic Stress Biosynthetic Demand Altered Metabolism Immune Evasion Cancer Phenotypes Dong 2019 . Inhibiting Heat Shock Factor 1 in Cancer: A Unique Therapeutic Opportu
Slide 11: Synthetic Lethality Interaction Between NXP800 and ARID1a
Synthetic Lethality Interaction Between NXP800 and ARID1a • The anti - tumor effect of NXP800 appears to be stronger in OCCC and endometrioid preclinical models that had the ARID1A mutation as compared to those without the mutation, suggesting the potential for Synthetic Lethality. • A synthetic let
Slide 12: NXP800 Demonstrated Substantial Antitumor Activity in OCCC Xenografts
NXP800 Demonstrated Substantial Antitumor Activity in OCCC Xenografts NXP800 inhibited tumor growth in OCCC xenograft models harboring an ARID1A mutation 12 SKOV - 3 TOV - 21G Published data on SKOV - 3 indicate that these tumors are platinum resistant SKOV - 3 treated with Cisplatin - Int J Mol Sci
Slide 13: OCCC and Advanced Endometrioid Ovarian Cancer: Unmet Medical Needs
OCCC and Advanced Endometrioid Ovarian Cancer Serious Conditions of Unmet Medical Needs 13 OCCC and Advanced Endometrioid Cancer Represent Unmet Medical Needs • Limited treatment options available. • Poor prognosis, low response rate to chemotherapy treatment.
Slide 14: OCCC and Endometrioid Ovarian Cancer Incidence
OCCC and endometrioid Ovarian Cancer Incidence 14 Ovarian Cancer Net Incidence by Type 10% 10% OCCC endometrioid The American Cancer Society estimates that approximately 21,410 women will receive a new diagnosis of ovarian cancer in the United States in 2021 ( https://cancerstatisticscenter.cancer.o
Slide 15: ARID1a Mutation Opportunity in Additional Tumor Types
ARID1a Mutation Opportunity in Additional Tumor Types 15 Indication Estimated Incidence (US) Patients with ARID1a protein loss (US) Uterine endometrioid 66,570 26,628 Urothelial 75,357 25,621 Hepatocellular 34,000 9,070 Gastric 26,550 6,615 Pancreatic 60,430 4,230 Esophageal 19,260 2,120 ARID1a is a
Slide 16: NXP800 Development Strategy
NXP800 Development Strategy • Clear cell and endometrioid ovarian cancers represent unmet medical needs and are our initial focus for clinical development. • ARID1a is mutated in multiple solid tumor types, potentially enabling a genetic mutation - based/tumor agnostic development opportunity utiliz
Slide 17: NXP900 Key Highlights
NXP900 Key Highlights 17 Unique mechanism of action Inhibits both the catalytic and scaffolding activities of the target kinases (SRC/YES1). NXP900 is differentiated from clinical - stage and approved multi - kinase inhibitors that also inhibit SRC because those only inhibit the catalytic activity o
Slide 18: NXP900 Novel and Differentiated Mechanism of Action
18 NXP900 Novel and Differentiated Mechanism of Action No inhibitor Fully active SRC Other multi - kinase inhibitors Partial shutdown of the SRC pathway NXP900 Induction of closed, inactive protein conformation resulting in complete shutdown of the SRC pathway
Slide 19: NXP900 Superior Preclinical Activity vs. Approved Compounds
19 NXP900 Superior Preclinical Activity vs. Approved Compounds NXP900 inhibited tumor growth in an orthotopic model of triple negative breast cancer (TNBC) in immunocompetent animals, showing superiority vs dasatinib, and substantial long - term effect after treatment completion. A,B) Comparative an
Slide 20: NXP900 Addresses the Shortcomings of Other SRC Inhibitors
NXP900 Addresses the Shortcomings of Other SRC Inhibitors 20 Unlocking the Full Potential of SRC Inhibition for the Treatment of Solid Tumors SRC overactivation is implicated in several solid tumors. However, the existing multi - kinase SRC inhibitors, including dasatinib, which is approved for CML/
Slide 21: NXP900 Potent Inhibition of YES1
NXP900 21 Potent Inhibition of YES1 YES1 gene amplification has been reported in diverse range of solid tumors, including lung, head and neck, bladder and esophageal cancers as a driver of the disease. YES1 amplification is one of several mechanisms of acquired resistance to EGFR inhibitors. YES1: A
Slide 22: Capitalization Table
Capitalization Table 22 Common Outstanding Pre - IPO 9,517,794* Options ($3.05 ) 226,590 Warrants ($3.05 ) 100,893 Restricted Stock Units 213,837 Fully Diluted Shares 10,059,114 * Includes 5,012,280 of preferred shares that automatically convert into common shares in this offering
Slide 23: Nuvectis Pharma Key Milestones
23 Nuvectis Pharma Key Milestones KEY MILESTONES NXP900 IND - enabling studies commencement expected in 4Q2021 NXP800 Phase I commencement expected in 4Q2021 Preclinical updates and publications expected throughout 2022
Slide 24: Precision Medicine Innovation: Key Highlights
24 Precision Medicine Innovation for Serious Conditions of Unmet Medical Needs in Oncology Key Highlights • Management team with a proven track record of clinical and regulatory success • 4 FDA approvals • 2 EU and 1 Japanese (via partner) approvals • Significant shareholder value creation • Unique